Slaoui resigns from Intellia's board

CRISPR company Intellia Therapeutics Inc. (NASDAQ:NTLA) said Moncef Slaoui resigned from its board on Aug. 7. In an SEC filing, Intellia said his resignation was due to a "conflict of interest" and "did not result from any disagreement with the company on any matter relating to the company’s operations, policies or practices."

Intellia announced Slaoui's board appointment on July 24. He was also to chair its science and technology committee...